CHIKUNGUNYA VIRUS-LIKE PARTICLE VACCINE AND METHODS OF USING THE SAME
The present disclosure is directed to improved virus-like particle (VLP) compositions and vaccines for use in inducing an immune response and/or protective immunity against a Chikungunya virus (CHIKV) infection in a subject, e.g., by inducing a neutralizing antibody response against CHIKV in a subject within 7 days after administration of a single dose of the composition or vaccine.
1 . A composition or vaccine comprising: (a) a virus-like particle (VLP) which comprises a capsid protein and an envelope protein derived from Chikungunya virus (CHIKV); (b) an aluminum hydroxide adjuvant; (c) a sugar; (d) a buffer and/or pH modifier; and (e) a carrier.
2 . A composition or vaccine comprising a virus-like particle (VLP) which comprises a capsid protein and an envelope protein derived from Chikungunya virus (CHIKV), wherein the composition or vaccine (i) induces a neutralizing antibody response against CHIKV in a subject within 7 days after administration of a single dose of the composition or vaccine to the subject and/or (ii) induces a neutralizing antibody response against CHIKV which persists for at least 28 days, at least 6 months, at least 1 year, or at least 2 years after a single dose is administered to the subject.
3 . The composition or vaccine of claim 2 , further comprising an adjuvant.
4 . The composition or vaccine of claim 3 , wherein the adjuvant is an aluminum hydroxide adjuvant.
5 . The composition or vaccine of any of claim 1 , 3 , or 4 , wherein the adjuvant is aluminum hydroxide gel.
6 . The composition or vaccine of any of the previous claims, wherein the capsid protein is a CHIKV C protein.
7 . The composition or vaccine of any of the previous claims, wherein the envelope protein is a CHIKV protein selected from the group consisting of E3, E2, 6K, E1, and any combination thereof.
8 . The composition or vaccine of any of the previous claims, wherein the VLP comprises CHIKV envelope proteins E2 and E1.
9 . The composition or vaccine of any of the previous claims, wherein the VLP comprises CHIKV C, E2, and E1 proteins.
10 . The composition or vaccine of claim 9 , wherein the CHIKV C, E2, and E1 proteins are at least 95% of the VLP proteins in the composition or vaccine.
11 . The composition or vaccine of any of the previous claims, wherein the VLP does not comprise CHIKV E3 and/or 6K.
12 . The composition or vaccine of any of the previous claims, wherein the capsid and envelope proteins are derived CHIKV strain 37997.
13 . The composition or vaccine of any of the previous claims which is a suspension suitable for intramuscular injection.
14 . The composition or vaccine of any of the previous claims, wherein a/the single dose of the composition or vaccine comprises about 6 μg to 200 μg VLP.
15 . The composition or vaccine of claim 14 , wherein the single dose of the composition or vaccine comprises about 20 μg to 100 μg VLP.
16 . The composition or vaccine of any of the previous claims, wherein a/the single dose of the composition or vaccine comprises about 25 μg/mL to 75 μg/mL VLP.
17 . The composition or vaccine of any one of claims 14 - 16 , wherein the single dose comprises about 40 μg or about 50 μg/mL VLP.
18 . The composition or vaccine of any one of claims 5 - 17 , wherein a/the single dose of the composition or vaccine comprises aluminum hydroxide gel in an amount of about 30 μg to 3000 μg.
19 . The composition or vaccine of claim 18 , wherein the single dose of the composition or vaccine comprises aluminum hydroxide gel in an amount of about 100 μg to 500 μg.
20 . The composition or vaccine of claim 18 or 19 , wherein the single dose comprises 250 μg/mL to 625 μg/mL aluminum hydroxide gel.
21 . The composition or vaccine of any one of claims 18 - 20 , wherein the single dose comprises about 300 μg or about 375 μg/mL aluminum hydroxide gel.
22 . The composition or vaccine of any of the previous claims, wherein a/the single dose of the composition or vaccine comprises a volume of about 0.5 mL to 2 mL.
23 . The composition or vaccine of claim 22 , wherein the single dose of the composition or vaccine comprises a volume of about 0.5 mL to 1 mL.
24 . The composition or vaccine of any of claims 2 - 23 , further comprising a sugar.
25 . The composition or vaccine of claim 24 , wherein the sugar is selected from the group consisting of sucrose, lactose, and any combination thereof.
26 . The composition or vaccine of claim 25 , where the sugar is sucrose.
27 . The composition or vaccine of any of claims 2 - 26 , further comprising a buffer and/or pH modifier.
28 . The composition or vaccine of claim 27 , where the buffer and/or pH modifier is selected from the group consisting of potassium phosphate monobasic, potassium phosphate dibasic, sodium citrate dehydrate, and any combination thereof.
29 . The composition or vaccine of any of the previous claims, wherein the composition or vaccine does not comprise a preservative or antibiotic.
30 . The composition or vaccine of any of the previous claims, wherein a/the single dose of the composition or vaccine comprises: (a) about 6 μg to 60 μg of the VLP and (b) about 200 μg to 500 μg of a/the aluminum hydroxide, wherein the single dose volume is between about 0.5 mL to 1.0 mL.
31 . The composition or vaccine of claim 30 , wherein the single dose of the composition or vaccine comprises: (a) about 6 μg to 60 μg of the VLP; (b) about 200 μg to 500 μg of the aluminum hydroxide; (c) about 20 mg to 80 mg of sucrose; (d) about 0.2 mg to 1.0 mg of potassium phosphate monobasic; (e) about 0.2 mg to 1.5 mg of potassium phosphate diabasic; (f) about 2 mg to 10 mg sodium citrate dehydrate; and (g) water, wherein the single dose volume is between about 0.5 mL to 1.0 mL.
32 . The composition or vaccine of any of the previous claims, wherein a/the single dose of the composition or vaccine is a volume of about 0.8 mL.
33 . The composition or vaccine of any of the previous claims, wherein the VLP induces antibodies against homologous or heterologous strains of CHIKV.
34 . The composition or vaccine of any of the previous claims, wherein the VLP induces antibodies against one or more CHIKV lineages selected from the group consisting of East/Central/South African (ECSA), West African and Asian.
35 . The composition or vaccine of claims 1 and 5 - 34 which induces a neutralizing antibody response against CHIKV in a subject within 7 days after administration of a/the single dose of the composition or vaccine to the subject.
36 . The composition or vaccine of any of claims 2 - 35 , wherein the neutralizing antibody response against CHIKV is sustained for at least 28 days after a/the single dose is administered.
37 . The composition or vaccine of claim 36 , wherein the neutralizing antibody response against CHIKV is sustained for at least six months after the single dose is administered.
38 . The composition or vaccine of claim 37 , wherein the neutralizing antibody response against CHIKV is sustained for at least one year, at least 18 months, or at least 2 years after the single dose is administered.
39 . The composition or vaccine of any of the previous claims, wherein the serum neutralizing antibody titer is ≥30 or ≥40 within 7 days after administration of a/the single dose of the composition or vaccine.
40 . The composition or vaccine of any of the previous claims, wherein the composition or vaccine induces a neutralizing antibody response against CHIKV in a subject within 7 days after administration of the single dose of the composition.
41 . The composition or vaccine of any of the previous claims, wherein the composition or vaccine induces a neutralizing antibody response against CHIKV which persists for at least 28 days, at least 6 months, at least 1 year, or at least 2 years after a single dose is administered to the subject.
42 . The composition or vaccine of any of the previous claims, wherein the composition or vaccine (i) induces a neutralizing antibody response against CHIKV in a subject within 7 days after administration of a single dose of the composition or vaccine to the subject and (ii) induces a neutralizing antibody response against CHIKV which persists for at least 28 days, at least 6 months, at least 1 year, or at least 2 years after a single dose is administered to the subject.
43 . A pre-filled syringe comprising a/the single dose of the composition or vaccine of any one of claims 1 - 42 .
44 . A method of inducing an immune response and/or protective immunity against Chikungunya virus (CHIKV) in a subject, comprising administering to the subject the composition or vaccine of any one of claims 1 - 42 .
45 . A method of inducing a neutralizing antibody response to Chikungunya virus (CHIKV) in a subject, comprising administering to the subject the composition or vaccine of any one of claims 1 - 42 .
46 . A method for treating, preventing, or reducing the risk of a Chikungunya infection in a subject, comprising administering to the subject an effective amount of the composition or vaccine of any one of claims 1 - 42 .
47 . A method of vaccinating a subject against a CHIKV infection, comprising administering to the subject an effective amount of the composition or vaccine of any one of claims 1 - 42 .
48 . A method of eliciting an immune response and/or protective immunity against Chikungunya virus (CHIKV) in a subject comprising: administering to the subject a composition or vaccine comprising (a) virus-like particles (VLPs) which comprise a capsid protein and an envelope protein derived from CHIKV and (b) an adjuvant, wherein a single dose of the composition or vaccine comprises about 6 μg to 200 μg VLPs, and wherein the administration of the single dose of the composition or vaccine (i) elicits production of CHIKV-specific neutralizing antibodies in the subject within 7 days of administration and/or (ii) induces a neutralizing antibody response against CHIKV which persists for at least 28 days, at least 6 months, at least 1 year, or at least 2 years after a single dose is administered to the subject.
49 . A method of inducing protective immunity against Chikungunya virus (CHIKV) in a population comprising: administering to the population a composition or vaccine comprising (a) virus-like particles (VLPs) which comprise a capsid protein and an envelope protein derived from CHIKV and (b) an adjuvant, wherein a single dose of the composition or vaccine comprises about 6 μg to 200 μg VLPs, and wherein at least 60% of the population (i) produces a neutralizing antibody response against CHIKV within 7 days after administration of the single dose of the composition or vaccine and/or (ii) produces neutralizing antibodies against CHIKV which persists for at least 28 days, at least 6 months, at least 1 year, or at least 2 years after a single dose is administered to the subject.
50 . The method of claim 49 , wherein at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, or at least 98% of the population develops a serum neutralizing antibody titer≥30 or ≥40 within 7 days after administration of a single dose of the composition or vaccine.
51 . The method of claim 49 or 50 , wherein at least 40%, at least 50%, or at least 60% of the population maintains a serum neutralizing antibody titer≥30 or ≥40 for at least 28 days, at least 6 months, at least one year, or at least two years after administration of a single dose of the composition or vaccine.
52 . The method of any one of claims 44 - 51 , wherein a/the single dose comprises 20 μg to 200 μg VLP.
53 . The method of any of claims 44 - 52 , wherein a/the single dose comprises about 25 μg/mL to 75 μg/mL VLP.
54 . The method of claim 53 , wherein the single dose comprises about 40 μg or about 50 μg/mL VLP.
55 . The method of any one of claims 44 - 54 , wherein the composition or vaccine comprises 30 μg-3000 μg aluminum hydroxide gel
56 . The method of claim 55 , wherein the aluminum hydroxide gel is in an amount of about 250 μg/mL to 625 μg/mL.
57 . The method of claim any one of claims 44 - 56 , wherein the composition or vaccine comprises about 300 μg or 375 μg/mL aluminum hydroxide gel.
58 . The method of any one of claims 44 - 57 , wherein the composition or vaccine comprises: (a) about 6 to 40 μg of VLP; (b) about 200 to 500 μg of aluminum hydroxide; (c) a sugar; (d) a buffer and/or a pH modifier; and (e) and water.
59 . The method of claim 58 , wherein the composition or vaccine comprises: (a) about 6 to 40 μg of VLP; (b) about 200 to 500 μg of aluminum hydroxide; (c) about 20 to 80 mg of sucrose; (d) about 0.2 to 1.0 mg of potassium phosphate monobasic; (e) about 0.2 to 1.5 mg of potassium phosphate diabasic; (f) about 2 to 10 mg sodium citrate dehydrate; and (g) and water.
60 . The method of any one of claims 44 - 59 , wherein a/the first dose is administered in an amount of about 0.5 mL to 1 mL.
61 . The method of claim 60 , wherein the first does is administered in an amount of about 0.8 mL.
62 . The method of any one of claims 44 - 61 , wherein the neutralizing antibody response vaccinates the subject against multiple serotypes of CHIKV.
63 . The method of any one of claims 44 - 62 , herein the neutralizing antibody response against CHIKV is sustained for at least 28 days, at least 6 months, at least 1 year, or at least 2 years after the single dose is administered.
64 . The method of any one of claims 44 - 63 , wherein a second dose of the composition or vaccine is administered to the subject at least 28 days, at least 6 months, or at least 1 year after the single dose.
65 . The method of claim 64 , wherein the neutralizing antibody response against CHIKV is sustained for at least six months after administration of the second dose.
66 . The method of claim 65 , wherein the neutralizing antibody response against CHIKV is sustained for at least one year after administration of the second dose.
67 . The method of any one of claims 44 - 66 , wherein at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% of the subjects produced a neutralizing antibody response to CHIKV 7 days after administration of the composition or vaccine.
68 . The method of any one of claims 44 - 67 , wherein the seroresponse rate is at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% 7 days, 28 days, one year, or two years after administration of the composition or vaccine.
69 . The method of any of one of claims 44 - 68 , wherein the serum neutralizing antibody titer is ≥30 or ≥40.
70 . The method of any one of claims 44 - 69 , wherein the composition or vaccine is administered intramuscularly.
71 . The method of any one of claims 44 - 70 , wherein the composition or vaccine is administered in an effective amount.
72 . The method of any one of claims 44 - 71 , wherein the method elicits production of CHIKV-specific neutralizing antibodies in the subject within 7 days of administration and induces the neutralizing antibody response against CHIKV which persists for at least 28 days, at least 6 months, at least 1 year, or at least 2 years after a single dose is administered to the subject.
73 . The composition, vaccine or method of any of the previous claims, wherein a/the subject is a human.
74 . The composition, vaccine or method of any of the previous claims, wherein a/the subject had no exposure to a CHIKV antigen or a CHIKV vaccine prior to administration of the composition or vaccine.
75 . The composition, vaccine or method of any of the previous claims, wherein a/the subject has no detectable CHIKV antibody titer prior to administration of the composition or vaccine.
76 . The composition, vaccine or method of any of the previous claims, wherein a/the subject has a detectable CHIKV antibody titer≤5 prior to administration of the composition or vaccine.